Chief Executive Officer, Hatchtech
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive Officer (former) | Hatchtech | GBS Ventures (21 Apr 2009), GBS Ventures (21 May 2007) |
Stories naming Dr Paul MacLeman. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech Hatchtech announced chief executive Paul MacLeman is resigning to lead another listed biotech; chairman Stewart Washer praised the head lice product's progress toward Phase II trials as a replacement is sought.
Melbourne biotech Cryptopharma completed an $800,000 round from GBS Venture Partners, Uniseed and ANU Connect for its cystic fibrosis drug, and appointed Dr David Crump CEO, with Dr Paul MacLeman moving to the board.
A trial of Hatchtech's DeOvoT head lice treatment found no side effects in its first human testing, with an FDA filing and a second-phase study planned and crop-spray work ongoing.